In the 1990’s USA: PSA Screening Reduced Instances of Initial Diagnosis of Metastatic Prostate Cancer By 50%

Screening for early cancer detection may reduce the rate of related metastatic disease, but not always. In a published study in the New England Journal of Medicine, researchers evaluated the incidence of men having a diagnosis of advanced, metastatic prostate cancer at the initial prostate cancer diagnosis. The researchers data from the Surveillance, Epidemiology, and End Results (SEER) Program database. Their analysis included only those men who had been diagnosed with advanced prostate cancer at diagnosis, not of early-stage disease that then progressed to metastasis. In this perspective study the authors describe trends in metastatic prostate cancer prior to and [...]

By | December 4th, 2016|advocacy, Biomarkers and Prognostic Tools, USPTF|0 Comments

Of Interest In the News – Surprise Out-of Network Bills and the U.S. Preventive Task Force Becomes Controversial

In an article in Time (3/7 Sweetland Edwards) there is a discussion about the failure of the Affordable Care Act to stop patients from receiving “surprise” bills from their medical providers for services provided. These surprises result from people going to a medical facility, which is in their Network but having some service, provided by an individual provider who is outside their network. This type of problem often results from the use of out of network labs and anesthesiologists who just show up and provide a service without the informed consent of the patient and the knowledge of the patient. [...]

By | March 9th, 2016|Insurance, Politics of Cancer, Uncategorized, USPTF|0 Comments

PSA Tests Cut Metastatic Prostate Cancer Rates by Half

Screening for early prostate cancer detection may reduce the rate of newly diagnosed  metastatic disease. In a published study researchers evaluated the incidence of a men receiving a diagnosis of metastatic prostate cancer at their initial prostate cancer diagnosis using data extracted from the Surveillance, Epidemiology, and End Results (SEER) Program database. Their analysis was of men diagnosed with advanced prostate cancer at diagnosis, not of early-stage disease that then progressed and became metastatic. In this perspective study, which was published in the New England Journal of Medicine, the authors describe trends in metastatic prostate cancer diagnosis prior to and [...]

By | February 17th, 2016|advocacy, Politics of Cancer, Uncategorized, USPTF|1 Comment

USPSTF Responds to Malecare’s Questions regarding PSA Screening

Malecare sent questions to Albert Siu, MD, Chairperson of the U.S. Preventive Services Task Force about plans to review their 2012 recommendation against the use of the PSA test for prostate cancer screening.  We thought that this information would be important since the USPTF is currently soliciting public comments on the research design of their review of their current D rating of the PSA as a screening tool.   Dr. Siu was quick to reply to us.  The following are is responses to our questions regarding how patient input might influence the recent call for comments regarding the USPSTF plan to [...]

By | November 11th, 2015|advocacy, PSA, USPTF|0 Comments
スーパーコピーブランド ロレックススーパーコピー オメガスーパーコピー ブルガリスーパーコピー ブライトリングスーパーコピー カルティエスーパーコピー シャネル時計コピー IWCスーパーコピー フランクミュラースーパーコピー パネライスーパーコピー タグホイヤースーパーコピー ウブロスーパーコピー ガガミラノスーパーコピー ルイヴィトンスーパーコピー シャネルスーパーコピー エルメススーパーコピー グッチスーパーコピー ボッテガヴェネタスーパーコピー プラダスーパーコピー セリーヌスーパーコピー ロレックススーパーコピー ウブロスーパーコピー